In the last decade, the management of breast cancer has shifted from primary surgical treatment to neoadjuvant systemic treatment (NST) in highly proliferative subtypes (human epidermal growth factor receptor 2 (HER2) positive, triple negative (TN), and some luminal B-like) [3,4,5]. This evidence concerns the gene ERBB2 and breast carcinoma.